FDA Grants Priority Review to KTE-C19 for Non-Hodgkin Lymphoma

May 26, 2017 – The FDA has granted a priority review to axicabtagene ciloleucel (KTE-C19; axi-cel) for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL), according to Kite Pharma, the developer of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The priority review was based on data from the phase II ZUMA-1 study, which was presented at the 2017 AACR Annual Meeting. In the study, axicabtagene ciloleucel … (leggi tutto)